Minimal GVHD following in-vitro Tcell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors

Experimental Hematology

Volumn 31, Issue 10, 2003, Pages 865-872

  Barge, Renée M Y ^a   Osanto, Susanne ^a   Marijt, W A F Erik ^a   Starrenburg, C W J Ingrid ^a   Fibbe, Willem E ^a   Nortier, J W R Hans ^a   Falkenburg, J H Frederik ^a   Willemze, Roel ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; RECOMBINANT ALPHA2A INTERFERON;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; IN VITRO STUDY; INCIDENCE; INCUBATION TIME; MALE; MORBIDITY; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SOLID TUMOR; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; THROMBOCYTOPENIA; VIRUS REACTIVATION;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 0141819097     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00200-5     Document Type: Article

References (32)

1. Weiden P.L., Sullivan K.M., Flournoy N., Storb R., Thomas E.D. Antileukemic effect of chronic graft-vs-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 304:1981;1529-1533.
2. Goldman J.M., Gale R.P., Horowaitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 108:1988;806-814.
3. + progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 95:1998;10152-10157.
4. Khouri I.F., Keating M., Körbling M., et al. Transplant-lite: Induction of graft-vs-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 16:(8):1998;2817-2824.
5. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematological diseases. Blood. 91:(3):1998;756-763.
6. Giralt S., Estey E., Albtar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-vs-leukemia without myeloablative therapy. Blood. 89:1997;4531-4536.
7. Storb R., Yu C., Sandmaier B.M., et al. Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting. Ann N Y Acad Sci. 872:1999;372-375.
8. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 97:2001;631-637.
9. Nagler A., Slavin S., Varadi G., Naparstek E., Samuel S., Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant. 25:2000;1021-1028.
10. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-vs-tumor effects. Blood. 97:2001;3390-3400.
11. Sandmaier B.M., Maloney D.G., Gooley T., et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: clinical results of a TBI-based conditioning regimen. [abstract] Blood. 98:(part 1):2001;742a-743a. Abstract 3093.
12. Mapara M.Y., Kim Y.M., Wang S.P., Bronson R., Sachs D.H., Sykes M. Donor lymphocyte infusions mediate superior graft-vs leukaemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood. 100:(5):2002;1903-1909.
13. + cells. Blood. 99:(11):2002;4174-4181.
14. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 339:1998;1186-1193.
15. Prigozhina T.B., Gurevitch O., Zhu J., Slavin S. Induction of mixed hematopoietic chimerism and specific transplantation tolerance to allogeneic and xenogeneic grafts by selective elimination of donor-reactive host cells following nonmyeloablative conditioning. Transplant Proc. 29:1997;2644-2646.
16. Barge R.M.Y., Brouwer R.E., Beersma M.F.C., et al. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome. Bone Marrow Transplant. 27:2001;1053-1058.
17. + cell determination by flow cytometry. J Hematother. 5:1996;213-226.
18. Boeckh M., Gooley T.H., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with Ganciclovir vs Ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 88:1996;4063-4071.
19. Marijt W.A.F., Barge R.M.Y., Fibbe W.E., et al. Combining α-interferon (α-IFN) with low dose donor lymphocyte infusion (DLI) for relapsed CML reduces the interval between DLI and complete remission (CR) and is associated with limited GVHD. [abstract] Blood. 96:(part 1):2000;196a. Abstract 840.
20. Glucksberg H., Storb R., Fefer A. Clinical manifestation of graft-vs-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation. 18:1974;295-304.
21. Shulman H.M., Sullivan K.M., Weiden P.L. Chronic graft-vs-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 69:1980;204-217.
22. Marijt W.A.F., Heemskerk M.H.M., Kloosterboer A.F., et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1 or HA-2 specific T cells can induce complete remissions of relapsed leukaemia. Proc Natl Acad Sci U S A. 100:(5):2003;2742-2747.
23. Anagnostopoulos A., Giralt S. Critical review on non-myeloablative stem cell transplantation (NST). Crit Rev Oncol Hematol. 44:2002;175-190.
24. Hale G., Waldmann H. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant. 17:1996;305-308.
25. Morris E.C., Rebello P., Thomson K.J., et al. Pharmacokinetics of alemtuzumab (CAMPATH-1H) used for in vivo and in vitro T-cell depletion in allogeneic transplants: relevance for early adoptive immunotherapy and infectious complications. Blood. 102:2003;404-406.
26. Passweg J.R., Meyer-Monard S., Gregor M., et al. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant. 30:2002;267-271.
27. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo CAMPATH-1H prevents graft-vs-host disease following nonmyeloablative stem cell transplantation. Blood. 96:(7):2000;2419-2425.
28. Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 99:(3):2002;1071-1078.
29. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 99:(12):2002;4357-4363.
30. Marks D.I., Lush R., Cavenagh J., et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 100:(9):2002;3108-3114.
31. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 343:(11):2000;750-758.
32. Rini B.I., Zimmerman T., Stadler W.M., Gajewski T.F., Vogelzang N.J. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol. 20:(8):2002;2017-2024.